history of glp 1 drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog History of GLP-1: From Discovery

Private employer plan GLP-1 coverage for obesity has become a major benefits policy debate, with large employers balancing the cost of GLP-1 coverage against documented workforce health and productivity benefits

doi: 10.3233/jad-2002-4605

Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions

In rare cases, the drugs can cause a critical organ, the pancreas, to inflame, or gallstones and gallbladder inflammation, kidney damage, bowel obstruction and intestinal paralysis, according to GoodRx, a free digital platform that allows users to compare prescription prices

Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression

Gastric emptying scintigraphy remains the gold standard, measuring the retention of a radiolabeled solid meal at standardized intervals (typically 0, 1, 2, and 4 hours post-ingestion) following the American Neurogastroenterology and Motility Society/Society of Nuclear Medicine and Molecular Imaging protocol